AgomAb Therapeutics NV American Depositary Shares - Asset Resilience Ratio
AgomAb Therapeutics NV American Depositary Shares (AGMB) has an Asset Resilience Ratio of 19.58% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read AgomAb Therapeutics NV American Deposita debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how AgomAb Therapeutics NV American Depositary Shares's Asset Resilience Ratio has changed over time. See net assets of AgomAb Therapeutics NV American Deposita for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down AgomAb Therapeutics NV American Depositary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AgomAb Therapeutics NV American Deposita (AGMB) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $30.10 Million | 19.58% |
| Total Liquid Assets | $30.10 Million | 19.58% |
Asset Resilience Insights
- Good Liquidity Position: AgomAb Therapeutics NV American Depositary Shares maintains a healthy 19.58% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
AgomAb Therapeutics NV American Depositary Shares Industry Peers by Asset Resilience Ratio
Compare AgomAb Therapeutics NV American Depositary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT |
Biotechnology | 63.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bio-Thera Solutions Ltd
SHG:688177 |
Biotechnology | 4.09% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Gubra A/S
CO:GUBRA |
Biotechnology | 79.61% |
Annual Asset Resilience Ratio for AgomAb Therapeutics NV American Depositary Shares (2021–2025)
The table below shows the annual Asset Resilience Ratio data for AgomAb Therapeutics NV American Depositary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.58% | $30.10 Million | $153.71 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $206.36 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $171.26 Million | -- |
| 2022-12-31 | 39.61% | $40.00 Million | $101.00 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $84.00 Million | -- |
About AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenos… Read more